Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(II) oxadiazoline complexes with potential cytotoxic properties

Studies on gold-nitrone systems

A series of novel Au(i)-nitrone complexes with specific catalytic properties were prepared. Furthermore, Au(i)- and Au(iii)-oxadiazole complexes were formed by a novel Au-generated nitrile-nitrone [3 + 2] cycloaddition, and the crystal structures of Au(i)-nitrones as well as the Au(i)- and Au(iii)-oxadiazole complexes were studied (X-ray). A useful one-pot Au(iii)-mediated cycloaddition method was developed for the formation of a number of dihydro-1,2,4-oxadiazoles, involving in situ formation of Au(iii)-oxadiazole complexes. The observed Au(i) and Au(iii) dual selective reactivity gives new understanding about the Au(i)- and Au(iii)-nitrone chemistry.

Synthesis, characterisation and in vitro cytotoxicity of mixed ligand Pt(ii) oxadiazoline complexes with hexamethylenetetramine and 7-nitro-1,3,5-triazaadamantane

trans-Platinum(ii) oxadiazoline complexes with 7-nitro-1,3,5-triazaadamantane (NO₂-TAA) or hexamethylenetetramine (hmta) ligands have been synthesised from trans-[PtCl₂(PhCN)₂] via cycloaddition of nitrones to one of the coordinated nitriles, followed by exchange of the other nitrile by NO₂-TAA or hmta. Stoichiometric control allows for the selective synthesis of mono- and dinuclear complexes where 7-NO₂TAA and hmta act as mono- and bidentate ligands, respectively. Precursors and the target complexes trans-[PtCl₂(hmta)(oxadiazoline)], trans-[PtCl₂(NO₂-TAA)(oxadiazoline)] and trans-[{PtCl₂(oxadiazoline)}₂(hmta)] were characterised by elemental analysis, IR and multinuclear (¹H, ¹³C, ¹⁹⁵Pt) NMR spectroscopy. DFT (B3LYP/6-31G*/LANL08) and AIM calculations suggest a stronger bonding of hmta with the [PtCl₂(oxadiazoline)] fragment, in agreement with the experimentally observed reactivity in the ligand exchange (hmta > 7-NO₂TAA). Replacement of the nitrile by hmta is predicted to be more exothermic than that with 7-NO₂-TAA, although the activation barriers are similar. Protonation of the non-coordinated N atoms is anticipated to weaken the Pt-N bond and lower the activation barrier for ligand exchange. This effect might help activate these compounds in a slightly acidic environment such as some tumour tissues. Ten of the new compounds were tested for their in vitro cytotoxicity in the human cancer cell lines HeLa and A549. Some of the mononuclear complexes are more potent than cisplatin, and their activity is still high in A549 where cisplatin shows little effect. The dinuclear complexes are inactive, presumably due to their lipophilicity and reduced solubility in water.

Dichloridobis[3-(4-meth-oxy-phen-yl)-2-methyl-5-(piperidin-1-yl)-2,3-di-hydro-1,2,4-oxa-diazole-κN (4)]platinum(II)

In title compound, [PtCl2(C15H21N3O2)2], the Pt(II) cation, located on an inversion center, is coordinated by two Cl(-) anions and two 3-(4-meth-oxy-phen-yl)-2-methyl-5-(piperidin-1-yl)-2,3-di-hydro-1,2,4-oxa-diazole ligands in a distorted Cl2N2 square-planar geometry. The di-hydro-oxa-diazole and piperidine rings display envelope (with the non-coordinating N atom as the flap atom) and chair conformations, respectively. In the crystal, weak C-H⋯Cl hydrogen bonds link the mol-ecules into supra-molecular chains running along the b axis. The piperidine ring is disordered over two positions with the occupancy ratio of 0.528 (4):0.472 (4).

Mechanism of the Pd-catalyzed decarboxylative allylation of α-imino esters: decarboxylation via free carboxylate ion

The Pd-catalyzed decarboxylative allylation of α-(diphenylmethylene)imino esters (1) or allyl diphenylglycinate imines (2) is an efficient method to construct new C(sp(3))-C(sp(3)) bonds. The detailed mechanism of this reaction was studied by theoretical calculations [ONIOM(B3LYP/LANL2DZ+p:PM6)] combined with experimental observations. The overall catalytic cycle was found to consist of three steps: oxidative addition, decarboxylation, and reductive allylation. The oxidative addition of 1 to [(dba)Pd(PPh(3))(2)] (dba = dibenzylideneacetone) produces an allylpalladium cation and a carboxylate anion with a low activation barrier of +9.1 kcal mol(-1). The following rate-determining decarboxylation proceeds via a solvent-exposed α-imino carboxylate anion rather than an O-ligated allylpalladium carboxylate with an activation barrier of +22.7 kcal mol(-1). The 2-azaallyl anion generated by this decarboxylation attacks the face of the allyl ligand opposite to the Pd center in an outer-sphere process to produce major product 3, with a lower activation barrier than that of the minor product 4. A positive linear Hammett correlation [ρ = 1.10 for the PPh(3) ligand] with the observed regioselectivity (3 versus 4) supports an outer-sphere pathway for the allylation step. When Pd combined with the bis(diphenylphosphino)butane (dppb) ligand is employed as a catalyst, the decarboxylation still proceeds via the free carboxylate anion without direct assistance of the cationic Pd center. Consistent with experimental observations, electron-withdrawing substituents on 2 were calculated to have lower activation barriers for decarboxylation and, thus, accelerate the overall reaction rates.